用甲胺酶向癌细胞的甲氨酸成
Vadim S Pokrovsky1,2,3, Louay Abo Qoura4,2, Elena A Demidova5
1Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, 115478, Russia. v.pokrovsky@ronc.ru.
Biochemistry. Biokhimiia
|September 26, 2023
概括
使用 metioninase (METase) 的 metionin 限制抑制了癌细胞的生长,而不会伤害正常细胞. 临床研究表明,口服复合甲基酶 (rMETase) 是治疗晚期癌症的安全有效疗法,单独或与化疗一起使用.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌细胞表现出对氨酸的代谢依赖,称为霍夫曼效应.
- 氨酸的限制有效地抑制了癌细胞的增殖,同时节省了正常细胞.
- 甲胺酶 (METase) 针对这种甲胺成,显示出作为癌症治疗的前景.
研究的目的:
- 审查关于在晚期癌症患者中以 metioninase 为媒介的 metionin 限制的临床研究.
- 分析口服复合甲基酶 (rMETase) 剂量的疗效和安全性.
- 评估rMETase作为独立补充剂或与化疗结合使用.
主要方法:
- 对8项已发表的关于METase在晚期癌症中的临床研究的综述.
- 对有关口服rMETase剂量方案的数据分析.
- 在单疗法和组合化疗环境中对METase的评估.
主要成果:
- 再组合甲基酶 (rMETase) 可以口服作为补充剂.
- 在晚期癌症患者中报告的事积极结果.
- 临床研究表明,METase是一种有效和安全的治疗方法.
结论:
- 通过METase限制 metionin是治疗晚期癌症的可行策略.
- 口服rMETase证明了安全性和有效性,无论单独还是与化疗一起.
- 对最佳的rMETase剂量进行进一步的研究是有必要的.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Phase II Reactions: Methylation Reactions
220
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
220
Electron Transport Chain: Complex I and II
14.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.3K


